透析患者抵抗性高血压:流行病学、诊断与管理
该综述指出,透析患者中表观治疗抵抗性高血压患病率约为18%至42%,但真性抵抗性高血压负担尚不明确。诊断需通过家庭或动态血压监测排除白大衣高血压及评估用药依从性;容量介导的高血压是最重要的可治疗抵抗原因,推荐限制饮食和透析液钠以实现干体重,而非单纯增加降压药数量。
要点
- 透析患者表观治疗抵抗性高血压患病率约18%至42%。
- 诊断需用家庭或动态血压监测排除白大衣效应并评估依从性。
- 容量介导的高血压是重要可治疗抵抗原因,应限钠并实现干体重。
核心结论
- 透析患者表观治疗抵抗性高血压常见,但真性抵抗性高血压负担不明。
- 容量介导的高血压是重要可治疗抵抗原因,应优先限钠和实现干体重而非增加降压药数量。
研究设计与样本
- 综述,检索范围未报告。
主要发现
- 维持性血液透析或腹膜透析患者中表观治疗抵抗性高血压患病率估计为18%至42%。
- 真性抵抗性高血压在透析人群中的负担仍未知,因缺乏对假性抵抗常见原因的严格评估。
关键数值与推荐
- 表观治疗抵抗性高血压定义为使用≥3种不同类别降压药仍血压升高,或无论血压水平使用≥4种降压药。
- 诊断评估包括用家庭或动态血压监测准确确定血压控制状态,并排除对处方降压方案不依从。
临床怎么用
- 对依从且使用最大耐受剂量β受体阻滞剂、长效二氢吡啶类钙通道阻滞剂和肾素-血管紧张素系统抑制剂仍血压控制不佳的透析患者,应识别并治疗容量超负荷。
- 推荐限制饮食和透析液钠以促进实现干体重,而非增加降压药数量。
- 通过至少4小时透析时间提供足够透析剂量以促进实现干体重。
局限性
- 真性抵抗性高血压在透析人群中的负担未知,因缺乏对假性抵抗常见原因的严格评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Apparent treatment-resistant hypertension is defined as an elevated BP despite the use of ≥3 antihypertensive medications from different classes or the use of ≥4 antihypertensives regardless of BP levels. Among patients receiving maintenance hemodialysis or peritoneal dialysis, using this definition, the prevalence of apparent treatment-resistant hypertension is estimated to be between 18% and 42%. Owing to the lack of a rigorous assessment of some common causes of pseudoresistance, the burden of true resistant hypertension in the dialysis population remains unknown. What distinguishes apparent treatment-resistance from true resistance is white-coat hypertension and adherence to medications. Accordingly, the diagnostic workup of a dialysis patient with apparent treatment-resistant hypertension on dialysis includes the accurate determination of BP control status with the use of home or ambulatory BP monitoring and exclusion of nonadherence to the prescribed antihypertensive regimen. In a patient on dialysis with inadequately controlled BP, despite adherence to therapy with maximally tolerated doses of a β -blocker, a long-acting dihydropyridine calcium channel blocker, and a renin-angiotensin system inhibitor, volume-mediated hypertension is the most important treatable cause of resistance. In daily clinical practice, such patients are often managed with intensification of antihypertensive therapy. However, this therapeutic strategy is likely to fail if volume overload is not adequately recognized or treated. Instead of increasing the number of prescribed BP-lowering medications, we recommend diet and dialysate restricted in sodium to facilitate achievement of dry weight. The achievement of dry weight is facilitated by an adequate time on dialysis of at least 4 hours for delivering an adequate dialysis dose. In this article, we review the epidemiology, diagnosis, and management of resistant hypertension among patients on dialysis.
引用
- Georgianos PI, Agarwal R. Resistant Hypertension in Dialysis: Epidemiology, Diagnosis, and Management. J Am Soc Nephrol. 2024. PMID: 38227447. doi:10.1681/ASN.0000000000000315
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。